Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210508051> ?p ?o ?g. }
- W4210508051 endingPage "445" @default.
- W4210508051 startingPage "427" @default.
- W4210508051 abstract "As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown. Here, we measured ex vivo sensitivity of 246 blood cancers to 63 drugs alongside genome, transcriptome, and DNA methylome analysis to understand determinants of drug response. We assembled a primary blood cancer cell encyclopedia data set that revealed disease-specific sensitivities for each cancer. Within chronic lymphocytic leukemia (CLL), responses to 62% of drugs were associated with 2 or more mutations, and linked the B cell receptor (BCR) pathway to trisomy 12, an important driver of CLL. Based on drug responses, the disease could be organized into phenotypic subgroups characterized by exploitable dependencies on BCR, mTOR, or MEK signaling and associated with mutations, gene expression, and DNA methylation. Fourteen percent of CLLs were driven by mTOR signaling in a non–BCR-dependent manner. Multivariate modeling revealed immunoglobulin heavy chain variable gene (IGHV) mutation status and trisomy 12 as the most important modulators of response to kinase inhibitors in CLL. Ex vivo drug responses were associated with outcome. This study overcomes the perception that most mutations do not influence drug response of cancer, and points to an updated approach to understanding tumor biology, with implications for biomarker discovery and cancer care." @default.
- W4210508051 created "2022-02-08" @default.
- W4210508051 creator A5000098098 @default.
- W4210508051 creator A5005029408 @default.
- W4210508051 creator A5005372827 @default.
- W4210508051 creator A5006107813 @default.
- W4210508051 creator A5008868111 @default.
- W4210508051 creator A5015238852 @default.
- W4210508051 creator A5015273169 @default.
- W4210508051 creator A5015790909 @default.
- W4210508051 creator A5015972472 @default.
- W4210508051 creator A5017545750 @default.
- W4210508051 creator A5018989565 @default.
- W4210508051 creator A5019957496 @default.
- W4210508051 creator A5020136143 @default.
- W4210508051 creator A5022268863 @default.
- W4210508051 creator A5022280742 @default.
- W4210508051 creator A5024900824 @default.
- W4210508051 creator A5026770080 @default.
- W4210508051 creator A5028013500 @default.
- W4210508051 creator A5029575769 @default.
- W4210508051 creator A5029601108 @default.
- W4210508051 creator A5032516884 @default.
- W4210508051 creator A5035103858 @default.
- W4210508051 creator A5040096832 @default.
- W4210508051 creator A5041510189 @default.
- W4210508051 creator A5044008222 @default.
- W4210508051 creator A5046828778 @default.
- W4210508051 creator A5055709980 @default.
- W4210508051 creator A5056243429 @default.
- W4210508051 creator A5057994815 @default.
- W4210508051 creator A5058238162 @default.
- W4210508051 creator A5059498954 @default.
- W4210508051 creator A5062544717 @default.
- W4210508051 creator A5063042751 @default.
- W4210508051 creator A5063431677 @default.
- W4210508051 creator A5063902452 @default.
- W4210508051 creator A5064177016 @default.
- W4210508051 creator A5067574718 @default.
- W4210508051 creator A5068603567 @default.
- W4210508051 creator A5069790818 @default.
- W4210508051 creator A5071297801 @default.
- W4210508051 creator A5077710470 @default.
- W4210508051 creator A5078894628 @default.
- W4210508051 creator A5079609030 @default.
- W4210508051 creator A5080107332 @default.
- W4210508051 creator A5081960245 @default.
- W4210508051 creator A5084073390 @default.
- W4210508051 creator A5086588914 @default.
- W4210508051 creator A5087195102 @default.
- W4210508051 creator A5087431460 @default.
- W4210508051 creator A5090815387 @default.
- W4210508051 creator A5091476155 @default.
- W4210508051 date "2017-12-11" @default.
- W4210508051 modified "2023-10-16" @default.
- W4210508051 title "Drug-perturbation-based stratification of blood cancer" @default.
- W4210508051 cites W1243376384 @default.
- W4210508051 cites W1441792155 @default.
- W4210508051 cites W1831873206 @default.
- W4210508051 cites W1969391810 @default.
- W4210508051 cites W1977342543 @default.
- W4210508051 cites W1978655536 @default.
- W4210508051 cites W1982535426 @default.
- W4210508051 cites W1997019712 @default.
- W4210508051 cites W2009937603 @default.
- W4210508051 cites W2011474181 @default.
- W4210508051 cites W2022054497 @default.
- W4210508051 cites W2026542427 @default.
- W4210508051 cites W2027774059 @default.
- W4210508051 cites W2033226263 @default.
- W4210508051 cites W2034351069 @default.
- W4210508051 cites W2043398720 @default.
- W4210508051 cites W2050574264 @default.
- W4210508051 cites W2066564017 @default.
- W4210508051 cites W2069682021 @default.
- W4210508051 cites W2071549499 @default.
- W4210508051 cites W2076393800 @default.
- W4210508051 cites W2082998819 @default.
- W4210508051 cites W2087312216 @default.
- W4210508051 cites W2088373095 @default.
- W4210508051 cites W2088388800 @default.
- W4210508051 cites W2089342610 @default.
- W4210508051 cites W2090505632 @default.
- W4210508051 cites W2098480759 @default.
- W4210508051 cites W2102074241 @default.
- W4210508051 cites W2103385435 @default.
- W4210508051 cites W2106543129 @default.
- W4210508051 cites W2108933868 @default.
- W4210508051 cites W2113895281 @default.
- W4210508051 cites W2115517051 @default.
- W4210508051 cites W2117661783 @default.
- W4210508051 cites W2125789330 @default.
- W4210508051 cites W2126244622 @default.
- W4210508051 cites W2136272158 @default.
- W4210508051 cites W2139573199 @default.
- W4210508051 cites W2140999266 @default.
- W4210508051 cites W2152883907 @default.
- W4210508051 cites W2153393011 @default.